Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Rating of "Hold" by Analysts

Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has been given a consensus rating of "Hold" by the nine brokerages that are presently covering the company, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $11.75.

A number of research analysts recently issued reports on INZY shares. TD Cowen cut shares of Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th. HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of Inozyme Pharma in a report on Thursday, April 10th. Wells Fargo & Company reissued an "equal weight" rating and issued a $4.00 price target on shares of Inozyme Pharma in a research report on Friday, May 16th. Jefferies Financial Group reaffirmed a "hold" rating and set a $4.00 price objective (down previously from $15.00) on shares of Inozyme Pharma in a research report on Friday, May 16th. Finally, Wedbush cut Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th.

Inozyme Pharma Stock Down 0.3%

Shares of INZY stock traded down $0.01 during midday trading on Monday, reaching $3.98. 1,032,624 shares of the stock were exchanged, compared to its average volume of 880,618. Inozyme Pharma has a 1 year low of $0.72 and a 1 year high of $6.24. The company's 50 day moving average is $1.99 and its two-hundred day moving average is $1.89. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. The firm has a market cap of $256.96 million, a PE ratio of -2.55 and a beta of 2.29.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). On average, equities research analysts predict that Inozyme Pharma will post -1.59 EPS for the current year.

Institutional Trading of Inozyme Pharma

Institutional investors have recently added to or reduced their stakes in the business. Harvest Investment Services LLC purchased a new position in shares of Inozyme Pharma in the fourth quarter worth $31,000. Graham Capital Management L.P. bought a new stake in Inozyme Pharma in the 4th quarter worth about $33,000. ProShare Advisors LLC purchased a new position in Inozyme Pharma in the 4th quarter worth about $49,000. D. E. Shaw & Co. Inc. bought a new position in Inozyme Pharma during the 4th quarter valued at about $49,000. Finally, Palumbo Wealth Management LLC lifted its stake in Inozyme Pharma by 52.3% during the 4th quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company's stock valued at $64,000 after acquiring an additional 7,995 shares during the period. 88.30% of the stock is currently owned by hedge funds and other institutional investors.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.